6 years of revenue, profit, cash flow and balance-sheet history through FY2024, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2024 | $8.3B | $149M | 27.1% | -0.2% | -$1.4B | $1.9B | $2M |
| 2023 | $6.8B | $115M | 23.0% | -5.7% | -$768M | $1.6B | $755000 |
| 2022 | $7.0B | $149M | 27.4% | 1.4% | -$806M | $1.2B | $5M |
| 2021 | $5.4B | -$991M | 0.0% | -8.7% | -$653M | $909M | — |
| 2020 | $3.3B | -$539M | 0.0% | -22.3% | -$440M | $911M | — |
| 2019 | $3.9B | $17M | 0.0% | 0.9% | $464000 | $342M | — |
How the market has priced MRM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Medirom Healthcare Technologies Inc.'s revenue has grown 16.3% per year, and net income grown 53.7% per year. These are computed facts, not advice.
As of FY2024, Medirom Healthcare Technologies Inc. reported $1.9B of total debt against $2M of cash; operating income covered interest expense -0.4×.
In FY2024, gross margin was 27.1%, operating margin -0.2%, and net margin 1.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.